Hao Y J, Natsume A, Mizuno M, Taniguchi K, Wakabayashi T, Yoshida J
Dept. of Neurosurgery, Nagoya University School of Medicine.
Gan To Kagaku Ryoho. 2000 Aug;27(9):1403-9.
The expression of topoisomerase II alpha (Topo II alpha) was investigated in six human glioma cell lines as a function of doubling time, cell cycle distribution, and sensitivity to an antineoplastic agent, etoposide (ETP). The Topo II alpha level was determined by immunohistochemical and flow cytometric studies using monoclonal antibody, 8D2, specific for Topo II alpha. In all cell lines, the Topo II alpha level correlated directly with sensitivity to ETP, but not with doubling time or percentage of cells in any phase of the cell cycle. These findings suggest that the cytocidal activity of ETP may be mediated by qualitative and quantitative changes in Topo II alpha in human glioma cells. We speculate that better knowledge of Topo II alpha expression in surgical specimens may lead to more individualized use of ETP in patients with malignant glioma.
研究了拓扑异构酶IIα（Topo IIα）在六种人类胶质瘤细胞系中的表达情况，该表达与倍增时间、细胞周期分布以及对抗肿瘤药物依托泊苷（ETP）的敏感性相关。使用针对Topo IIα的单克隆抗体8D2，通过免疫组织化学和流式细胞术研究确定Topo IIα水平。在所有细胞系中，Topo IIα水平与对ETP的敏感性直接相关，但与倍增时间或细胞周期任何阶段的细胞百分比无关。这些发现表明，ETP的杀细胞活性可能由人类胶质瘤细胞中Topo IIα的定性和定量变化介导。我们推测，更好地了解手术标本中Topo IIα的表达情况可能会使恶性胶质瘤患者更个体化地使用ETP。
